MedPath

Dietary Intervention for Low Free Sugars in Children With Non-alcoholic Fatty Liver Disease

Not Applicable
Completed
Conditions
NAFLD
Low-free Sugar Dietary
Child Obesity
Interventions
Behavioral: Dietary intervention for low free sugars
Registration Number
NCT06579729
Lead Sponsor
China Medical University, China
Brief Summary

A 48-week dietary intervention program was conducted in children aged 5-14 years with a diagnosis of NAFLD, who were randomized into a low free sugar diet group and a regular diet group. The primary objective of this study is to determine whether a low free sugar dietary intervention program improves liver function, fasting glucose, fasting insulin, lipid profile and hepatic steatosis in children with NAFLD. The effects of the intervention will be analyzed and compared at weeks 12, 24 and 48.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
146
Inclusion Criteria
  • Age: above 5 years old and below 14 years old;
  • Guardian's consent and signing of informed consent;
  • WHO growth and development curves as the reference standard, overweight is defined as BMI greater than or equal to the 85th percentile of the WHO growth curves for children, and obesity is defined as BMI greater than or equal to the 95th percentile of the WHO growth curves for children;
  • Liver imaging performance meets the diagnostic criteria of diffuse fatty liver.
Exclusion Criteria
  • Age <5 years or >14 years;
  • Previous history of alcohol consumption;
  • Non-cooperation with the study, inability to comply with the study treatment or study visit.
  • Past or active hepatitis B virus infection;
  • Past or active hepatitis C virus infection;
  • Chronic or acute liver failure;
  • Cholestasis;
  • Hepatomegaly;
  • Cystic fibrosis;
  • α1-antitrypsin deficiency;
  • Autoimmune hepatitis;
  • Tyrosinemia;
  • Galactosemia or any recognized liver disease, any physical condition deemed by a physician to be unable to complete the trial. Physical Condition.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intervention groupDietary intervention for low free sugars-
Primary Outcome Measures
NameTimeMethod
NAFLDAt weeks 1, 12 and 24

NAFLD was diagnosed using liver ultrasonography with a Phillip IU Elite color Doppler ultrasound after a fasting period to reduce gastrointestinal interference.

DietaryAt weeks 1, 12 and 24

The dietary habits of the subjects were evaluated by a semi-quantitative Food Frequency Questionnaire (FFQ), which was recalled over the past month and included food items, frequency, and amount of intake. The FFQ used in this study covered 72 food items from 11 food groups and 4 frequency categories, including 'average daily, weekly, monthly intake or hardly eat'.

Physical activity levelAt weeks 1, 12 and 24

Physical Activity Questionnaire for Children (PAQ-C) was answered by subjects. The PAQ-C reflects the overall physical activity level of children in the past 7 days.The scale consists of 10 items, .and a 1-5 scale was used to obtain a total score by summing the scores of the individual items. The PAQ-C scale scores \< 2.33 defined as low physical activity levels, 2.33-3.66 as moderate physical activity levels, and \>3.66 as high physical activity levels.

Secondary Outcome Measures
NameTimeMethod
HeightAt weeks 1, 12 and 24

Height was measured using Height Measuring Ruler (Selcom, Germany) .

Body weightAt weeks 1, 12 and 24

Body weight was measured using Body Composition Analyzer (DC-13, Parade, Japan).

BMIAt weeks 1, 12 and 24

BMI (kg/m2) = body weight (kg)/height2 (m2).

Waist circumferenceAt weeks 1, 12 and 24

Waist circumference was measured with circumference measuring tape.

Waist-to-height ratioAt weeks 1, 12 and 24

Waist-to-height ratio (WHtR) = waist circumference (cm)/height (cm).

Blood pressureAt weeks 1, 12 and 24

Blood pressure was measured using an Omron electronic blood pressure monitor (HBP-1300).

Trial Locations

Locations (1)

China Medical University

🇨🇳

Shenyang, China

© Copyright 2025. All Rights Reserved by MedPath